HRP20200285T1 - Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom - Google Patents
Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom Download PDFInfo
- Publication number
- HRP20200285T1 HRP20200285T1 HRP20200285TT HRP20200285T HRP20200285T1 HR P20200285 T1 HRP20200285 T1 HR P20200285T1 HR P20200285T T HRP20200285T T HR P20200285TT HR P20200285 T HRP20200285 T HR P20200285T HR P20200285 T1 HRP20200285 T1 HR P20200285T1
- Authority
- HR
- Croatia
- Prior art keywords
- subtype
- nucleic acid
- preparation
- acid encoding
- vaccine combination
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 3
- 230000001939 inductive effect Effects 0.000 title claims 2
- 230000001681 protective effect Effects 0.000 title claims 2
- 208000007136 Filoviridae Infections Diseases 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 229960005486 vaccine Drugs 0.000 claims 9
- 241000711950 Filoviridae Species 0.000 claims 7
- 241000701161 unidentified adenovirus Species 0.000 claims 7
- 102000003886 Glycoproteins Human genes 0.000 claims 5
- 108090000288 Glycoproteins Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241001115402 Ebolavirus Species 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (9)
1. Kombinacija cjepiva koja sadrži
(i) prvi pripravak koji sadrži imunološki efikasnu količinu vektora adenovirusa koji sadrži nukleinsku kiselinu koja šifrira antigeni glikoprotein prvog podtipa filovirusa, pri čemu spomenuti prvi podtip filovirusa je podtip Ebolavirusa, zajedno s farmaceutski prihvatljivim nosačem; i
(ii) drugi pripravak koji sadrži imunološki efikasnu količinu MVA vektora koji sadrži nukleinsku kiselinu koja šifrira antigeni glikoprotein podtipa Ebolavirusa te dodatno šifrira barem jedan antigeni protein drugog podtipa filovirusa, zajedno s farmaceutski prihvatljivim nosačem;
za uporabu u izazivanju zaštitnog imunološkog odaziva protiv barem jednog podtipa Ebolavirusa, pri čemu se prvi pripravak koristi za izazivanje imunološkog odaziva protiv barem jednog podtipa Ebolavirusa te se drugi pripravak koristi za pojačavanje spomenutog imunološkog odziva.
2. Kombinacija cjepiva za uporabu prema zahtjevu 1, pri čemu spomenuti pripravak (i) dalje sadrži vektor adenovirusa koji sadrži nukleinsku kiselinu koja šifrira antigeni protein drugog podtipa filovirusa.
3. Kombinacija cjepiva za uporabu prema zahtjevu 2, pri čemu prvi pripravak (i) dalje sadrži vektor adenovirusa koji sadrži nukleinsku kiselinu koja šifrira antigeni protein trećeg podtipa filovirusa.
4. Kombinacija cjepiva za uporabu prema zahtjevu 1, pri čemu vektor adenovirusa u prvom pripravaku (i) sadrži nukleinsku kiselinu koja šifrira antigeni glikoprotein sa SEQ ID NO:1.
5. Kombinacija cjepiva za uporabu prema zahtjevu 4, pri čemu pripravak (i) dalje sadrži adenovirus koji sadrži nukleinsku kiselinu koja šifrira antigeni glikoprotein sa SEQ ID NO:2.
6. Kombinacija cjepiva za uporabu prema zahtjevu 5, pri čemu pripravak (i) dalje sadrži adenovirus koji sadrži nukleinsku kiselinu koja šifrira antigeni glikoprotein sa SEQ ID NO:3.
7. Kombinacija cjepiva za uporabu prema bilo kojem od zahtjeva 1-6, pri čemu MVA vektor u pripravaku (ii) sadrži nukleinsku kiselinu koja šifrira antigene proteine barem četiri podtipa filovirusa.
8. Kombinacija cjepiva za uporabu prema bilo kojem od zahtjeva 1-7, pri čemu MVA vektor u pripravaku (ii) sadrži nukleinsku kiselinu koja šifrira antigene proteine barem četiri različita podtipa filovirusa koji imaju SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4 i SEQ ID NO: 5.
9. Kombinacija cjepiva za uporabu prema bilo kojem od zahtjeva 1-8, pri čemu je vektor adenovirusa rAd26 ili rAd35 vektor.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045522P | 2014-09-03 | 2014-09-03 | |
| US201562116021P | 2015-02-13 | 2015-02-13 | |
| US201562189109P | 2015-07-06 | 2015-07-06 | |
| PCT/US2015/048357 WO2016036955A1 (en) | 2014-09-03 | 2015-09-03 | Methods and compositions for inducing protective immunity against filovirus infection |
| EP15767631.3A EP3188753B1 (en) | 2014-09-03 | 2015-09-03 | Methods and compositions for inducing protective immunity against filovirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200285T1 true HRP20200285T1 (hr) | 2020-08-07 |
Family
ID=54186280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240163TT HRP20240163T1 (hr) | 2014-09-03 | 2015-09-03 | Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom |
| HRP20200285TT HRP20200285T1 (hr) | 2014-09-03 | 2020-02-19 | Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240163TT HRP20240163T1 (hr) | 2014-09-03 | 2015-09-03 | Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10561721B2 (hr) |
| EP (2) | EP3188753B1 (hr) |
| JP (1) | JP6462861B2 (hr) |
| KR (1) | KR101963985B1 (hr) |
| CN (1) | CN107454848B (hr) |
| AU (1) | AU2015311852B2 (hr) |
| BR (1) | BR112017003891A2 (hr) |
| CA (1) | CA2960092C (hr) |
| DK (2) | DK3656395T3 (hr) |
| EA (1) | EA035504B1 (hr) |
| ES (1) | ES2777323T3 (hr) |
| FI (1) | FI3656395T3 (hr) |
| HR (2) | HRP20240163T1 (hr) |
| HU (1) | HUE048318T2 (hr) |
| IL (1) | IL250743B (hr) |
| LT (2) | LT3188753T (hr) |
| MX (1) | MX2017002889A (hr) |
| MY (1) | MY183072A (hr) |
| NZ (1) | NZ730511A (hr) |
| PL (2) | PL3656395T3 (hr) |
| PT (2) | PT3188753T (hr) |
| SG (1) | SG11201701741QA (hr) |
| SI (2) | SI3188753T1 (hr) |
| UA (1) | UA125013C2 (hr) |
| WO (1) | WO2016036955A1 (hr) |
| ZA (1) | ZA201701815B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023098A1 (en) * | 2016-05-05 | 2017-11-09 | The Trustees Of The University Of Pennsylvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| US10925955B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a Marburg virus infection |
| WO2018011768A1 (en) * | 2016-07-15 | 2018-01-18 | Janssen Vaccines And Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
| CA3083576A1 (en) * | 2017-09-07 | 2019-03-14 | Hawaii Biotech, Inc. | Filovirus vaccine and methods of use |
| WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| JP2023516201A (ja) | 2020-03-12 | 2023-04-18 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスの安定性を改善する組成物 |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| WO2000000616A2 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| WO2000008131A2 (en) * | 1998-08-04 | 2000-02-17 | Purdue Research Foundation | Pseudotyped retroviruses and stable cell lines for their production |
| KR100741247B1 (ko) | 1999-05-17 | 2007-07-19 | 크루셀 홀란드 비.브이. | 아데노바이러스 타입 35의 적어도 하나의 구성성분을포함하는 아데노바이러스 유래 유전자 전달체 |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| DK1335987T4 (en) | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
| JP2005517639A (ja) * | 2001-11-30 | 2005-06-16 | イシス イノベーション リミテッド | ワクチン |
| CN101397574A (zh) | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| DK1497438T3 (da) | 2002-04-25 | 2010-01-04 | Crucell Holland Bv | Midler og fremgangsmåder til fremstilling af adenovirusvektorer |
| PL208588B1 (pl) | 2002-04-25 | 2011-05-31 | Crucell Holland Bv | Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa |
| PL2163260T3 (pl) | 2004-01-23 | 2017-12-29 | Msd Italia S.R.L. | Szympansie adenowirusowe nośniki szczepionek |
| JP5046941B2 (ja) | 2004-09-27 | 2012-10-10 | アメリカ合衆国 | エボラ及び他のウイルスに対する防御に最適化されたワクチン |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| US8603468B2 (en) | 2007-11-06 | 2013-12-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Neutralization of HCV |
| WO2010057650A1 (en) * | 2008-11-21 | 2010-05-27 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
| KR101763093B1 (ko) | 2009-02-02 | 2017-07-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도 |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| EP2529010B1 (en) | 2010-01-28 | 2017-04-19 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of mva |
| WO2011130627A2 (en) * | 2010-04-16 | 2011-10-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
| US9701718B2 (en) * | 2010-12-14 | 2017-07-11 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| WO2012106490A1 (en) * | 2011-02-03 | 2012-08-09 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Multivalent vaccines for rabies virus and filoviruses |
| KR20220012403A (ko) * | 2012-04-12 | 2022-02-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| WO2014005643A1 (en) * | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| GB201303406D0 (en) | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 JP JP2017512990A patent/JP6462861B2/ja active Active
- 2015-09-03 EP EP15767631.3A patent/EP3188753B1/en active Active
- 2015-09-03 WO PCT/US2015/048357 patent/WO2016036955A1/en active Application Filing
- 2015-09-03 UA UAA201703034A patent/UA125013C2/uk unknown
- 2015-09-03 IL IL250743A patent/IL250743B/en unknown
- 2015-09-03 PT PT157676313T patent/PT3188753T/pt unknown
- 2015-09-03 BR BR112017003891A patent/BR112017003891A2/pt not_active Application Discontinuation
- 2015-09-03 PT PT192167732T patent/PT3656395T/pt unknown
- 2015-09-03 MX MX2017002889A patent/MX2017002889A/es unknown
- 2015-09-03 HR HRP20240163TT patent/HRP20240163T1/hr unknown
- 2015-09-03 PL PL19216773.2T patent/PL3656395T3/pl unknown
- 2015-09-03 KR KR1020177008911A patent/KR101963985B1/ko active IP Right Grant
- 2015-09-03 CN CN201580047578.5A patent/CN107454848B/zh active Active
- 2015-09-03 ES ES15767631T patent/ES2777323T3/es active Active
- 2015-09-03 SI SI201531108T patent/SI3188753T1/sl unknown
- 2015-09-03 DK DK19216773.2T patent/DK3656395T3/da active
- 2015-09-03 SI SI201531986T patent/SI3656395T1/sl unknown
- 2015-09-03 DK DK15767631.3T patent/DK3188753T3/da active
- 2015-09-03 MY MYPI2017700699A patent/MY183072A/en unknown
- 2015-09-03 NZ NZ730511A patent/NZ730511A/en unknown
- 2015-09-03 PL PL15767631T patent/PL3188753T3/pl unknown
- 2015-09-03 LT LTEP15767631.3T patent/LT3188753T/lt unknown
- 2015-09-03 SG SG11201701741QA patent/SG11201701741QA/en unknown
- 2015-09-03 AU AU2015311852A patent/AU2015311852B2/en active Active
- 2015-09-03 EA EA201790517A patent/EA035504B1/ru unknown
- 2015-09-03 US US15/507,975 patent/US10561721B2/en active Active
- 2015-09-03 CA CA2960092A patent/CA2960092C/en active Active
- 2015-09-03 HU HUE15767631A patent/HUE048318T2/hu unknown
- 2015-09-03 EP EP19216773.2A patent/EP3656395B1/en active Active
- 2015-09-03 LT LTEP19216773.2T patent/LT3656395T/lt unknown
- 2015-09-03 FI FIEP19216773.2T patent/FI3656395T3/fi active
-
2017
- 2017-03-14 ZA ZA2017/01815A patent/ZA201701815B/en unknown
-
2019
- 2019-10-17 US US16/655,516 patent/US11173201B2/en active Active
-
2020
- 2020-02-19 HR HRP20200285TT patent/HRP20200285T1/hr unknown
-
2021
- 2021-10-11 US US17/450,465 patent/US11918639B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200285T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom | |
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| HRP20210608T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije | |
| MX342716B (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| SG10201903538YA (en) | Modified virus-like particles of cmv | |
| BR112016019525A2 (pt) | construções de proteína uspa2 e seu uso | |
| EA201790507A1 (ru) | Способы и композиции для усиления иммунных ответов | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| WO2015052543A3 (en) | Malaria vaccination | |
| WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| MX370715B (es) | Vacuna de subunidades anti-mycoplasma spp. | |
| NZ700470A (en) | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof | |
| MX2020011586A (es) | Virus vaccinia quimerico sintetico. | |
| WO2011150320A3 (en) | Activators of innate immunity | |
| CL2012003219A1 (es) | Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal. | |
| PH12015501721A1 (en) | Porcine parvovirus 5b, methods of use and vaccine | |
| PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
| WO2014060851A3 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
| Kobayashi | Requirements of new vaccines against novel influenza viruses | |
| EA202191862A2 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| ZA201700164B (en) | Influenza virus vaccines and uses thereof | |
| MX2019015700A (es) | Vacuna de subunidades anti-mycoplasma spp. | |
| MX2019015698A (es) | Vacuna de subunidades anti-mycoplasma spp. | |
| MX2019015697A (es) | Vacuna de subunidades anti-mycoplasma spp. |